C4 Imaging LLC

C4 Imaging develops innovative MRI-visible fiducial markers for precision cancer treatment and image-guided procedures. The company's core proprietary technology is a unique magnetic resonance imaging agent encapsulated within an implantable, biocompatible shell. C4 Imaging markets three primary products: SIRIUS for Low Dose Rate (LDR) Brachytherapy prostate seed localization, ORION for High Dose Rate (HDR) Brachytherapy, and NOVA for Proton Therapy and External Beam Radiation Therapy. These non-metallic markers reduce image distortion compared to conventional markers, enabling accurate tumor localization and treatment planning while eliminating artifacts in MRI-CT fusion workflows. The markers improve quality assurance in radiation oncology by allowing post-implant visualization with MRI alone, reducing the need for CT imaging. Founded in 2010 by Dr. Steven J. Frank, a Professor of Radiation Oncology at MD Anderson Cancer Center, C4 Imaging serves the radiation oncology community with solutions for safer, more effective cancer care.